Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with …
C Ortega, RKS Wong, J Schaefferkoetter… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The aim of this study was to determine whether quantitative PET parameters on baseline
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of
therapy are predictive of the therapy response and progression-free survival (PFS).
Methods: Ninety-one patients with well-differentiated neuroendocrine tumors (mean Ki-67
index, 8.3%) underwent 68Ga-DOTATATE PET/CT to determine suitability for peptide
receptor radionuclide therapy as part of a prospective multicenter study. The mean follow-up …
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of
therapy are predictive of the therapy response and progression-free survival (PFS).
Methods: Ninety-one patients with well-differentiated neuroendocrine tumors (mean Ki-67
index, 8.3%) underwent 68Ga-DOTATATE PET/CT to determine suitability for peptide
receptor radionuclide therapy as part of a prospective multicenter study. The mean follow-up …
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with …
U Metser, C Ortega, P Veit-Haibach, J Schaefferkoetter… - 2021 - Soc Nuclear Med
1379 Purpose: To determine whether quantitative PET parameters on baseline 68 Ga-
DOTATATE PET/CT (bPET) and interim PET (iPET) performed prior to second cycle of
therapy are predictive of therapy response and progression free survival (PFS). PATIENTS &
METHODS: Ninety-one patients with well-differentiated neuroendocrine tumors (mean Ki67,
8.3%) underwent 68 Ga-DOTATATE PET/CT (DT-PET) to determine suitability for peptide
receptor radionuclide therapy (PRRT) as part of a prospective multicenter study. Mean follow …
DOTATATE PET/CT (bPET) and interim PET (iPET) performed prior to second cycle of
therapy are predictive of therapy response and progression free survival (PFS). PATIENTS &
METHODS: Ninety-one patients with well-differentiated neuroendocrine tumors (mean Ki67,
8.3%) underwent 68 Ga-DOTATATE PET/CT (DT-PET) to determine suitability for peptide
receptor radionuclide therapy (PRRT) as part of a prospective multicenter study. Mean follow …
以上显示的是最相近的搜索结果。 查看全部搜索结果